Abrysvo
(RSV Vaccine)ApprovedVaccine
Johnson & JohnsonThis vaccine helps protect against serious respiratory illness caused by RSV, a common virus. It works by training your immune system to recognize and fight the RSV virus, reducing the risk of severe lower respiratory tract disease, particularly in older adults and other high-risk groups.[2] Abrysvo is currently approved and in use across 1 indication[4].[1]
Abrysvo is one of 2 biologic programs targeting RSV. It is currently in Approved.
1
Indications
8
Total Trials
2
Active Trials
1
Competitors
Pipeline
Status by Indication[4][1]
Competition
Competitive Landscape
3 competitors in RSV
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Respiratory Syncytial Virus (RSV)3 trials
Pregnancy2 trials
Immunogenicity1 trial
Pregnant Women1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Abrysvo drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for RSV Vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[3]
- Highest Phase
- Approved[1]
- Company